Whilst CTLA-4 blockade results in a plethora of immune adverse reactions including potentially fatal colitis, the sustained overall response in 20.8% of patients at 3 years provides an impetus to investigate the use of this agent in the adjuvant setting. Here, CTLA4 is linked to colitis.